{"gene":"FMO2","run_date":"2026-04-28T17:46:04","timeline":{"discoveries":[{"year":1998,"finding":"The major human FMO2 allele contains a C→T nonsense mutation at codon 472, producing a truncated 471-amino-acid polypeptide that lacks 64 C-terminal residues; heterologous expression demonstrated this truncated protein is catalytically inactive. The mutation is absent in closely related primates (gorilla, chimpanzee), indicating it arose after Homo–Pan divergence.","method":"cDNA cloning, sequencing, heterologous expression in vitro, comparative primate genomics","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution/expression with direct catalytic assay, replicated across species comparisons","pmids":["9804831"],"is_preprint":false},{"year":1994,"finding":"Rabbit FMO2 expressed in E. coli catalyzes the sulfoxidation of alkyl p-tolyl sulfides with high substrate affinity (Km <10 µM) and a unique stereochemical profile distinct from FMO1, FMO3, and FMO5; FMO5 produced no detectable sulfoxide product under the same conditions.","method":"cDNA expression in E. coli, kinetic (Km, Vmax) and stereochemical (enantiomeric excess) analysis of sulfoxidation products","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with kinetic characterization and stereochemical readout","pmids":["8203899"],"is_preprint":false},{"year":2001,"finding":"Baculovirus-expressed full-length rhesus macaque FMO2 (mFMO2-535) is catalytically active in N- and S-oxygenation assays, whereas the 3′-truncated form (mFMO2-471, equivalent to the human truncation at AA471) correctly localizes to the membrane fraction but shows no detectable N- or S-oxygenase activity, confirming the C-terminal region is essential for catalysis.","method":"Baculovirus expression, subcellular fractionation, N-oxygenation and S-oxygenation enzyme assays, pH/temperature/detergent stability profiling","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 — reconstituted full-length vs. truncated proteins with direct enzyme assays and multiple functional parameters","pmids":["11302936"],"is_preprint":false},{"year":2000,"finding":"In African-Americans heterozygous for the functional FMO2*1 (1414C) allele, immunoreactive full-length FMO2 protein is detectable in pulmonary microsomes by Western blot, confirming the 1414C allele encodes an active enzyme in vivo; individuals homozygous for 1414T lack detectable protein. A second frameshift allele (T1589 insertion) segregates with 1414T and does not further affect FMO2 activity.","method":"Genotyping (PCR), Western blot of pulmonary microsomes, FMO activity assay","journal":"Toxicology and applied pharmacology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal genotype–protein–activity correlation with Western blot and enzyme assay in human tissue","pmids":["11042094"],"is_preprint":false},{"year":2002,"finding":"Laboratory rat FMO2 contains a double deletion (nt 1263–1264) causing a frameshift and premature stop at position 432; heterologous expression of this cDNA yields a catalytically inactive protein, and the truncated protein is only faintly detectable in rat lung by Western blot.","method":"cDNA cloning and sequencing, heterologous expression, Western blot, Northern blot","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — expression with direct enzyme assay demonstrating inactivity of truncated protein","pmids":["11906197"],"is_preprint":false},{"year":2009,"finding":"The S195L variant of human FMO2.1 shows a ~12-fold increase in Km for NADPH relative to the reference Gln472 protein, markedly reduced activity at elevated pH or with cholate, and heat-labile activity that is rescued by NADPH, consistent with disrupted NADP(+) interactions; the N413K variant has the same activity pattern as Gln472 but with increased Vmax and kcat.","method":"Baculovirus expression of SNP variants, kinetic analysis (Km, Vmax, kcat), pH/temperature/cholate/Mg2+ stability assays, structural modeling","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzyme kinetics with multiple conditions and structural modeling, characterizing catalytic mechanism","pmids":["19420133"],"is_preprint":false},{"year":2015,"finding":"Human FMO2 expressed in E. coli whole-cell biocatalysts catalyzes the selective N-oxidation of trifluoperazine to its N1-oxide and oxidizes propranolol; truncation of the C-terminal membrane-anchor region did not yield soluble FMO2 but affected recombinant protein levels.","method":"Heterologous expression in E. coli, substrate screening, biotransformation at 100 L scale with product isolation and purity analysis","journal":"Microbial cell factories","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with preparative-scale catalytic demonstration and product characterization","pmids":["26062974"],"is_preprint":false},{"year":2023,"finding":"FMO2 directly interacts with SREBP1 at amino acids 217–296 of FMO2, competitively displacing SCAP from SREBP1, thereby blocking SREBP1 translocation from the ER to the Golgi and its subsequent proteolytic activation, thus suppressing de novo lipogenesis. This function is independent of FMO2 enzymatic activity. Hepatocyte-specific FMO2 knockout exacerbated steatosis, and FMO2 overexpression ameliorated NAFLD in mice.","method":"Co-IP, pulldown mapping (aa 217–296), hepatocyte-specific and global KO/overexpression mouse models, RNA-seq, SREBP1 translocation assay, competitive binding assay with SCAP","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 1–2 — direct protein interaction mapping + competitive binding + KO/OE mouse phenotype with mechanistic readout, multiple orthogonal methods","pmids":["37874228"],"is_preprint":false},{"year":2025,"finding":"FMO2 localizes to mitochondria-associated ER membranes (MAMs) in cardiomyocytes and forms a complex with IP3R2, Grp75, and VDAC1, maintaining ER–mitochondria contacts and regulating mitochondrial Ca2+ transfer for bioenergetics. FMO2 deletion worsened, and cardiac-specific FMO2 overexpression prevented, pathological cardiac hypertrophy in mice.","method":"MAM-targeted mass spectrometry, Co-IP (IP3R2-Grp75-VDAC1 complex), cardiac-specific KO and AAV9-overexpression mouse models, Ca2+ signaling assay, neonatal rat cardiomyocyte culture","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1–2 — MAM proteomics + Co-IP complex identification + KO/OE mouse phenotype with defined Ca2+ mechanism","pmids":["40489543"],"is_preprint":false},{"year":2025,"finding":"FMO2 protects against doxorubicin-induced cardiomyopathy by stabilizing chromatin-associated XLF (XRCC4-like factor), thereby promoting DNA double-strand break repair. FMO2 KO exacerbated DOX-induced cardiac injury; cardiomyocyte-specific FMO2 overexpression mitigated it without compromising antitumor efficacy.","method":"FMO2 KO and cardiomyocyte-specific overexpression mouse models, transcriptome profiling, chromatin analysis, XLF stability assays, xenograft tumor model","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — KO/OE mouse models with defined molecular mechanism (XLF stabilization), single lab","pmids":["40752568"],"is_preprint":false},{"year":2025,"finding":"FMO2 promotes angiogenesis in endothelial cells by regulating N-acetylornithine levels; N-acetylornithine inactivates NOTCH1 expression via transcriptional regulation of ATF3. EC-specific FMO2 compensation in FMO2-knockout mice restored angiogenesis in ischemic models and developing retina.","method":"Single-cell transcriptomics, EC-specific KO compensation, targeted metabolomics, NOTCH1/ATF3 transcriptional assay, ischemic model in vivo","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — metabolomics + genetic rescue + transcriptional mechanism, single lab","pmids":["41053533"],"is_preprint":false},{"year":2025,"finding":"FMO2 promotes CCL19 expression in cancer-associated fibroblasts by competitively binding GYS1 (glycogen synthase 1), thereby preventing the PJA1 ubiquitin ligase from targeting GYS1 for proteasomal degradation; accumulated GYS1 activates NF-κB/p65-mediated CCL19 transcription, which drives tertiary lymphoid structure formation and CD8+ T cell/M1 macrophage infiltration.","method":"Co-IP (FMO2-GYS1-PJA1), ubiquitination assay, NF-κB/p65 reporter, mouse orthotopic HCC model, single-cell RNA-seq, spatial transcriptomics, CyTOF","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP interaction mapping + ubiquitination assay + in vivo rescue, single lab","pmids":["40316306"],"is_preprint":false},{"year":2025,"finding":"CELF4 RNA-binding protein binds the 3′UTR of FMO2 mRNA, suppressing FMO2 expression; reduced FMO2 levels potentiate Smad2/3 phosphorylation downstream of TGF-β1 in cardiac fibroblasts, promoting fibrosis. CELF4 KO upregulated FMO2 and attenuated cardiac fibrosis.","method":"RNA pull-down, luciferase reporter assay (3′UTR), RIP assay, CELF4 KO mouse model, TGF-β1-stimulated cardiac fibroblasts, Western blot","journal":"BMC cardiovascular disorders","confidence":"Medium","confidence_rationale":"Tier 2–3 — RNA pull-down + luciferase + in vivo KO with defined signaling readout, single lab","pmids":["40610856"],"is_preprint":false},{"year":2025,"finding":"CELF1 RNA-binding protein binds FMO2 mRNA and its 3′UTR GU-rich element, promoting FMO2 mRNA decay; CELF1 silencing upregulated FMO2 and improved post-MI cardiac remodeling, while FMO2 overexpression reduced extracellular matrix deposition.","method":"RIP assay, RNA pull-down (biotinylated GU-rich element), actinomycin D mRNA stability assay, LAD-ligation MI mouse model, lentiviral FMO2 overexpression","journal":"Cardiovascular toxicology","confidence":"Medium","confidence_rationale":"Tier 2–3 — RNA pull-down + mRNA stability + in vivo KO/OE with defined phenotype, single lab","pmids":["40021568"],"is_preprint":false},{"year":2024,"finding":"Exercise training upregulates cardiac FMO2 through an AMPK→KLF4 transcriptional axis; KLF4 mediates FMO2 transcription; AAV9-mediated FMO2 knockdown abolished exercise-mediated cardiac protection against sympathetic overactivation-induced dysfunction and fibrosis.","method":"AAV9 FMO2 knockdown in vivo, AMPK activation experiments, KLF4 transcription factor identification, mouse model of sympathetic overactivation","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KD with defined upstream pathway and functional cardiac phenotype, single lab","pmids":["39491669"],"is_preprint":false}],"current_model":"Human FMO2 is an NADPH-dependent flavoenzyme that, when full-length (FMO2*1 allele), catalyzes N- and S-oxygenation of xenobiotics in the lung; the predominant human allele encodes a catalytically inactive C-terminally truncated protein, but beyond its classical enzymatic role, full-length FMO2 also acts as a non-enzymatic scaffold that blocks SREBP1 ER-to-Golgi translocation to suppress hepatic lipogenesis, maintains ER–mitochondria (MAM) contacts via the IP3R2-Grp75-VDAC1 complex to regulate mitochondrial Ca2+ signaling, stabilizes chromatin-bound XLF to facilitate DNA repair in cardiomyocytes, and in cancer-associated fibroblasts sequesters GYS1 from PJA1-mediated ubiquitination to activate NF-κB/CCL19 signaling."},"narrative":{"teleology":[{"year":1994,"claim":"Establishing FMO2 as a catalytically distinct monooxygenase: recombinant rabbit FMO2 showed unique sulfoxidation kinetics and stereoselectivity compared with other FMO family members, defining it as a functionally autonomous enzyme rather than a redundant paralog.","evidence":"E. coli–expressed rabbit FMO2 with kinetic (Km, Vmax) and enantiomeric excess measurements of sulfoxidation products","pmids":["8203899"],"confidence":"High","gaps":["Human FMO2 substrate spectrum not yet characterized","No structural basis for stereoselectivity"]},{"year":1998,"claim":"Explaining why most humans lack pulmonary FMO2 activity: identification of the Q472X nonsense mutation in the major human allele showed the C-terminal region is indispensable for catalysis, a conclusion confirmed by expression of the equivalent truncation in macaque FMO2.","evidence":"cDNA cloning/sequencing, heterologous expression with catalytic assays, and primate comparative genomics [1998]; baculovirus-expressed macaque full-length vs. truncated FMO2 [2001]; genotype–protein–activity correlation in human lung microsomes [2000]","pmids":["9804831","11302936","11042094"],"confidence":"High","gaps":["Structural mechanism by which C-terminal truncation abolishes catalysis unknown","Frequency of functional FMO2*1 in non-African populations not established"]},{"year":2009,"claim":"Defining catalytic residues and cofactor interactions: characterization of S195L and N413K variants revealed that S195 is critical for NADPH binding affinity, refining the mechanistic model of FMO2 cofactor utilization.","evidence":"Baculovirus-expressed SNP variants with full kinetic profiling (Km for NADPH, Vmax, kcat) and thermal/pH/detergent stability assays","pmids":["19420133"],"confidence":"High","gaps":["No crystal structure of FMO2 to confirm predicted cofactor contacts","Impact of these variants in vivo unknown"]},{"year":2023,"claim":"Revealing an enzyme-independent scaffolding role in lipid metabolism: FMO2 directly binds SREBP1 (aa 217–296) and competitively displaces SCAP, blocking SREBP1 ER-to-Golgi translocation and suppressing de novo lipogenesis — a function independent of its monooxygenase activity.","evidence":"Co-IP with domain mapping, competitive binding assay, hepatocyte-specific KO/OE mouse models with NAFLD phenotyping, RNA-seq","pmids":["37874228"],"confidence":"High","gaps":["Whether the truncated Q472X protein retains SREBP1-binding capacity is untested","Regulation of FMO2 expression in hepatocytes not defined"]},{"year":2024,"claim":"Identifying the upstream transcriptional axis controlling cardiac FMO2: exercise-induced AMPK activation drives KLF4-mediated FMO2 transcription, and AAV9-mediated FMO2 knockdown abolished exercise-conferred cardiac protection.","evidence":"AAV9 FMO2 knockdown in vivo, AMPK activation experiments, KLF4 transcription factor identification, sympathetic overactivation mouse model","pmids":["39491669"],"confidence":"Medium","gaps":["Direct KLF4 binding to FMO2 promoter not shown by ChIP","Whether AMPK–KLF4 axis operates in non-cardiac tissues unknown"]},{"year":2025,"claim":"Establishing FMO2 as a MAM-resident scaffold for ER–mitochondria Ca²⁺ signaling: FMO2 localizes to MAMs and forms a complex with IP3R2–Grp75–VDAC1, maintaining mitochondrial Ca²⁺ transfer; cardiac-specific KO exacerbated and OE prevented pathological hypertrophy.","evidence":"MAM-targeted proteomics, Co-IP of complex components, cardiac-specific KO and AAV9-OE mouse models, Ca²⁺ imaging in neonatal rat cardiomyocytes","pmids":["40489543"],"confidence":"High","gaps":["Stoichiometry and direct vs. bridged interaction with each complex member unresolved","Whether MAM function is enzymatic or purely scaffolding not dissected"]},{"year":2025,"claim":"Linking FMO2 to DNA repair: FMO2 stabilizes chromatin-bound XLF to facilitate NHEJ-mediated DNA double-strand break repair, protecting cardiomyocytes from doxorubicin-induced damage.","evidence":"FMO2 KO and cardiomyocyte-specific OE mouse models, chromatin analysis, XLF stability assays, xenograft tumor model","pmids":["40752568"],"confidence":"Medium","gaps":["Mechanism of XLF stabilization (direct binding vs. indirect) not defined","Single-lab finding awaiting independent replication"]},{"year":2025,"claim":"Revealing a non-enzymatic role in immune microenvironment remodeling: in cancer-associated fibroblasts, FMO2 sequesters GYS1 from PJA1-mediated ubiquitination, enabling GYS1 accumulation that activates NF-κB/p65-driven CCL19 transcription and tertiary lymphoid structure formation.","evidence":"Co-IP (FMO2–GYS1–PJA1), ubiquitination assay, NF-κB reporter, orthotopic HCC mouse model, scRNA-seq, spatial transcriptomics, CyTOF","pmids":["40316306"],"confidence":"Medium","gaps":["FMO2–GYS1 binding interface not mapped","Relevance outside hepatocellular carcinoma unclear","Single-lab finding"]},{"year":2025,"claim":"Defining post-transcriptional regulation of FMO2: CELF1 and CELF4 independently bind FMO2 mRNA (3′UTR GU-rich elements) and promote its decay, establishing mRNA stability as a key regulatory node for FMO2 levels in cardiac fibroblasts.","evidence":"RIP, RNA pull-down with biotinylated elements, luciferase 3′UTR reporter, actinomycin D decay assay, CELF KO/KD mouse models with cardiac phenotyping","pmids":["40021568","40610856"],"confidence":"Medium","gaps":["Whether CELF1 and CELF4 target overlapping or distinct sites on FMO2 3′UTR not compared","Impact of post-transcriptional regulation on non-cardiac FMO2 functions untested"]},{"year":null,"claim":"It remains unknown how FMO2's multiple non-enzymatic scaffold functions (SREBP1 binding, MAM tethering, XLF stabilization, GYS1 sequestration) are coordinated or mutually exclusive across cell types, and whether the prevalent Q472X truncated human protein retains any of these scaffold activities.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of human FMO2 to map overlapping vs. separate interaction surfaces","Truncated Q472X protein has never been tested for non-enzymatic functions","No systems-level study integrating enzymatic and scaffolding roles across tissues"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[1,2,5,6]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,8,11]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[7,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[8]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2,7,8]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,8,11,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,9]}],"complexes":["IP3R2-Grp75-VDAC1 MAM complex"],"partners":["SREBP1","SCAP","IP3R2","GRP75","VDAC1","XLF","GYS1","PJA1"],"other_free_text":[]},"mechanistic_narrative":"FMO2 is a multifunctional ER-anchored flavoprotein that serves both as an NADPH-dependent monooxygenase catalyzing N- and S-oxygenation of xenobiotics and as a non-enzymatic scaffold regulating lipid metabolism, calcium signaling, DNA repair, and immune signaling. The full-length enzyme (encoded by the FMO2*1 allele) requires its C-terminal 64 residues for catalytic activity, as the predominant human allele (Q472X) produces a truncated, catalytically inactive protein that nonetheless localizes to ER membranes [PMID:9804831, PMID:11302936]. Independent of its enzymatic function, FMO2 competitively displaces SCAP from SREBP1 to block ER-to-Golgi translocation and suppress hepatic lipogenesis [PMID:37874228], maintains ER–mitochondria contacts via an IP3R2–Grp75–VDAC1 complex to regulate mitochondrial Ca²⁺ transfer in cardiomyocytes [PMID:40489543], stabilizes chromatin-bound XLF to promote DNA double-strand break repair [PMID:40752568], and sequesters GYS1 from PJA1-mediated ubiquitination to activate NF-κB/CCL19 signaling in cancer-associated fibroblasts [PMID:40316306]. FMO2 expression is transcriptionally induced by the AMPK–KLF4 axis and post-transcriptionally suppressed by the RNA-binding proteins CELF1 and CELF4, which promote FMO2 mRNA decay via 3′UTR binding [PMID:39491669, PMID:40021568, PMID:40610856]."},"prefetch_data":{"uniprot":{"accession":"Q99518","full_name":"Flavin-containing monooxygenase 2","aliases":["Dimethylaniline oxidase 2","FMO 1B1","Pulmonary flavin-containing monooxygenase 2","FMO 2"],"length_aa":535,"mass_kda":60.9,"function":"Catalyzes the oxidative metabolism of numerous xenobiotics, including mainly therapeutic drugs and insecticides that contain a soft nucleophile, most commonly nitrogen and sulfur and participates to their bioactivation (PubMed:15144220, PubMed:15294458, PubMed:18930751, PubMed:18948378, PubMed:9804831). Specifically catalyzes S-oxygenation of sulfur derived compounds such as thioureas-derived compounds, thioetherorganophosphates to their sulfenic acid (PubMed:15144220, PubMed:9804831). In vitro, catalyzes S-oxygenation of the second-line antitubercular drugs thiacetazone (TAZ) and ethionamide (ETA), forming a sulfinic acid and a carbodiimide via a postulated sulfenic acid intermediate (PubMed:18930751, PubMed:18948378). Also catalyzes S-oxygenation of the thioether-containing organophosphate insecticides, phorate and disulfoton (PubMed:15294458)","subcellular_location":"Microsome membrane; Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q99518/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FMO2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FMO2","total_profiled":1310},"omim":[{"mim_id":"603957","title":"FLAVIN-CONTAINING DIMETHYLANILINE MONOOXYGENASE 5; FMO5","url":"https://www.omim.org/entry/603957"},{"mim_id":"603955","title":"FLAVIN-CONTAINING DIMETHYLANILINE MONOOXYGENASE 2; FMO2","url":"https://www.omim.org/entry/603955"},{"mim_id":"136131","title":"FLAVIN-CONTAINING DIMETHYLANILINE MONOOXYGENASE 4; FMO4","url":"https://www.omim.org/entry/136131"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":65.4},{"tissue":"blood vessel","ntpm":93.7},{"tissue":"lung","ntpm":74.8}],"url":"https://www.proteinatlas.org/search/FMO2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P31512","domains":[{"cath_id":"3.50.50.60","chopping":"5-152_333-418","consensus_level":"high","plddt":95.3283,"start":5,"end":418},{"cath_id":"3.50.50.60","chopping":"156-328","consensus_level":"high","plddt":94.9161,"start":156,"end":328}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P31512","model_url":"https://alphafold.ebi.ac.uk/files/AF-P31512-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P31512-F1-predicted_aligned_error_v6.png","plddt_mean":91.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FMO2","jax_strain_url":"https://www.jax.org/strain/search?query=FMO2"},"sequence":{"accession":"P31512","fasta_url":"https://rest.uniprot.org/uniprotkb/P31512.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P31512/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P31512"}},"corpus_meta":[{"pmid":"9804831","id":"PMC_9804831","title":"The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9804831","citation_count":104,"is_preprint":false},{"pmid":"11042094","id":"PMC_11042094","title":"Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans.","date":"2000","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11042094","citation_count":67,"is_preprint":false},{"pmid":"1417778","id":"PMC_1417778","title":"Cloning, primary sequence and chromosomal localization of human FMO2, a new member of the flavin-containing mono-oxygenase family.","date":"1992","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1417778","citation_count":52,"is_preprint":false},{"pmid":"23583631","id":"PMC_23583631","title":"Hypoxia inducible factor-1 (HIF-1)-flavin containing monooxygenase-2 (FMO-2) signaling acts in silver nanoparticles and silver ion toxicity in the nematode, Caenorhabditis elegans.","date":"2013","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23583631","citation_count":38,"is_preprint":false},{"pmid":"18234543","id":"PMC_18234543","title":"CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma--a pilot study.","date":"2008","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18234543","citation_count":36,"is_preprint":false},{"pmid":"8203899","id":"PMC_8203899","title":"Prochiral sulfoxidation as a probe for multiple forms of the microsomal flavin-containing monooxygenase: studies with rabbit FMO1, FMO2, FMO3, and FMO5 expressed in Escherichia coli.","date":"1994","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/8203899","citation_count":33,"is_preprint":false},{"pmid":"11302936","id":"PMC_11302936","title":"Characterization of expressed full-length and truncated FMO2 from rhesus monkey.","date":"2001","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/11302936","citation_count":29,"is_preprint":false},{"pmid":"8786146","id":"PMC_8786146","title":"Localization of human flavin-containing monooxygenase genes FMO2 and FMO5 to chromosome 1q.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8786146","citation_count":27,"is_preprint":false},{"pmid":"15355885","id":"PMC_15355885","title":"Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent.","date":"2004","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15355885","citation_count":24,"is_preprint":false},{"pmid":"9061021","id":"PMC_9061021","title":"Pulmonary flavin-containing monooxygenase (FMO) in rhesus macaque: expression of FMO2 protein, mRNA and analysis of the cDNA.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9061021","citation_count":22,"is_preprint":false},{"pmid":"15864117","id":"PMC_15864117","title":"Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics.","date":"2005","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/15864117","citation_count":20,"is_preprint":false},{"pmid":"37874228","id":"PMC_37874228","title":"FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1.","date":"2023","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/37874228","citation_count":17,"is_preprint":false},{"pmid":"11906197","id":"PMC_11906197","title":"The FMO2 gene of laboratory rats, as in most humans, encodes a truncated protein.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11906197","citation_count":17,"is_preprint":false},{"pmid":"26062974","id":"PMC_26062974","title":"Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis.","date":"2015","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/26062974","citation_count":15,"is_preprint":false},{"pmid":"8971137","id":"PMC_8971137","title":"Structural characteristics of flavin-containing monooxygenase genes one and two (FMO1 and FMO2).","date":"1996","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/8971137","citation_count":9,"is_preprint":false},{"pmid":"40316306","id":"PMC_40316306","title":"FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma.","date":"2025","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40316306","citation_count":8,"is_preprint":false},{"pmid":"19420133","id":"PMC_19420133","title":"Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.","date":"2009","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/19420133","citation_count":8,"is_preprint":false},{"pmid":"40489543","id":"PMC_40489543","title":"FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1.","date":"2025","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/40489543","citation_count":6,"is_preprint":false},{"pmid":"15454729","id":"PMC_15454729","title":"Identification and characterization of the FMO2 gene in Rattus norvegicus: a good model to study metabolic and toxicological consequences of the FMO2 polymorphism.","date":"2004","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15454729","citation_count":6,"is_preprint":false},{"pmid":"36318393","id":"PMC_36318393","title":"The FMO2 analysis of the ligand-receptor binding energy: the Biscarbene-Gold(I)/DNA G-Quadruplex case study.","date":"2022","source":"Journal of computer-aided molecular design","url":"https://pubmed.ncbi.nlm.nih.gov/36318393","citation_count":5,"is_preprint":false},{"pmid":"28981537","id":"PMC_28981537","title":"An ancestral human genetic variant linked to an ancient disease: A novel association of FMO2 polymorphisms with tuberculosis (TB) in Ethiopian populations provides new insight into the differential ethno-geographic distribution of FMO2*1.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28981537","citation_count":5,"is_preprint":false},{"pmid":"37814902","id":"PMC_37814902","title":"Circ_MACF1 targets miR-421 to upregulate FMO2 to suppress paclitaxel resistance and malignant cellular behaviors in lung adenocarcinoma.","date":"2023","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37814902","citation_count":3,"is_preprint":false},{"pmid":"41053533","id":"PMC_41053533","title":"FMO2 Promotes Angiogenesis via Regulation of N-Acetylornithine.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41053533","citation_count":1,"is_preprint":false},{"pmid":"40610856","id":"PMC_40610856","title":"CUGBP Elav-like family member 4 promotes cardiac remodeling through Inhibition of FMO2.","date":"2025","source":"BMC cardiovascular disorders","url":"https://pubmed.ncbi.nlm.nih.gov/40610856","citation_count":1,"is_preprint":false},{"pmid":"40752568","id":"PMC_40752568","title":"FMO2 expression confers cardioprotection in doxorubicin therapy while preserving antitumor activity.","date":"2025","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/40752568","citation_count":1,"is_preprint":false},{"pmid":"39867229","id":"PMC_39867229","title":"Perception of Enterococcus faecalis without infection induces fmo-2 in C. elegans.","date":"2025","source":"microPublication biology","url":"https://pubmed.ncbi.nlm.nih.gov/39867229","citation_count":1,"is_preprint":false},{"pmid":"40021568","id":"PMC_40021568","title":"CELF1 Promotes Post-myocardial Infarction Cardiac Remodeling Via Suppression of FMO2.","date":"2025","source":"Cardiovascular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/40021568","citation_count":0,"is_preprint":false},{"pmid":"39491669","id":"PMC_39491669","title":"Exercise training attenuates cardiac dysfunction induced by excessive sympathetic activation through an AMPK-KLF4-FMO2 axis.","date":"2024","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/39491669","citation_count":0,"is_preprint":false},{"pmid":"41134904","id":"PMC_41134904","title":"Metabolic regulation of behavior by the intestinal enzyme FMO-2.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/41134904","citation_count":0,"is_preprint":false},{"pmid":"41702017","id":"PMC_41702017","title":"The 1 -Cys peroxiredoxin, PRDX-6, suppresses an NHR-49-dependent pro-survival response, including the Flavin monooxygenase, FMO-2, that protects against fungal and bacterial infection.","date":"2025","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/41702017","citation_count":0,"is_preprint":false},{"pmid":"41960420","id":"PMC_41960420","title":"Mild mitochondrial impairment activates overlapping longevity pathways converging on the flavin-containing monooxygenase FMO-2.","date":"2026","source":"Frontiers in aging","url":"https://pubmed.ncbi.nlm.nih.gov/41960420","citation_count":0,"is_preprint":false},{"pmid":"41726866","id":"PMC_41726866","title":"Mild Mitochondrial Impairment Activates Overlapping Longevity Pathways Converging on the Flavin-Containing Monooxygenase FMO-2.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41726866","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18379,"output_tokens":3921,"usd":0.056976},"stage2":{"model":"claude-opus-4-6","input_tokens":7386,"output_tokens":2986,"usd":0.16737},"total_usd":0.224346,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"The major human FMO2 allele contains a C→T nonsense mutation at codon 472, producing a truncated 471-amino-acid polypeptide that lacks 64 C-terminal residues; heterologous expression demonstrated this truncated protein is catalytically inactive. The mutation is absent in closely related primates (gorilla, chimpanzee), indicating it arose after Homo–Pan divergence.\",\n      \"method\": \"cDNA cloning, sequencing, heterologous expression in vitro, comparative primate genomics\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution/expression with direct catalytic assay, replicated across species comparisons\",\n      \"pmids\": [\"9804831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Rabbit FMO2 expressed in E. coli catalyzes the sulfoxidation of alkyl p-tolyl sulfides with high substrate affinity (Km <10 µM) and a unique stereochemical profile distinct from FMO1, FMO3, and FMO5; FMO5 produced no detectable sulfoxide product under the same conditions.\",\n      \"method\": \"cDNA expression in E. coli, kinetic (Km, Vmax) and stereochemical (enantiomeric excess) analysis of sulfoxidation products\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with kinetic characterization and stereochemical readout\",\n      \"pmids\": [\"8203899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Baculovirus-expressed full-length rhesus macaque FMO2 (mFMO2-535) is catalytically active in N- and S-oxygenation assays, whereas the 3′-truncated form (mFMO2-471, equivalent to the human truncation at AA471) correctly localizes to the membrane fraction but shows no detectable N- or S-oxygenase activity, confirming the C-terminal region is essential for catalysis.\",\n      \"method\": \"Baculovirus expression, subcellular fractionation, N-oxygenation and S-oxygenation enzyme assays, pH/temperature/detergent stability profiling\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted full-length vs. truncated proteins with direct enzyme assays and multiple functional parameters\",\n      \"pmids\": [\"11302936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In African-Americans heterozygous for the functional FMO2*1 (1414C) allele, immunoreactive full-length FMO2 protein is detectable in pulmonary microsomes by Western blot, confirming the 1414C allele encodes an active enzyme in vivo; individuals homozygous for 1414T lack detectable protein. A second frameshift allele (T1589 insertion) segregates with 1414T and does not further affect FMO2 activity.\",\n      \"method\": \"Genotyping (PCR), Western blot of pulmonary microsomes, FMO activity assay\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal genotype–protein–activity correlation with Western blot and enzyme assay in human tissue\",\n      \"pmids\": [\"11042094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Laboratory rat FMO2 contains a double deletion (nt 1263–1264) causing a frameshift and premature stop at position 432; heterologous expression of this cDNA yields a catalytically inactive protein, and the truncated protein is only faintly detectable in rat lung by Western blot.\",\n      \"method\": \"cDNA cloning and sequencing, heterologous expression, Western blot, Northern blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — expression with direct enzyme assay demonstrating inactivity of truncated protein\",\n      \"pmids\": [\"11906197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The S195L variant of human FMO2.1 shows a ~12-fold increase in Km for NADPH relative to the reference Gln472 protein, markedly reduced activity at elevated pH or with cholate, and heat-labile activity that is rescued by NADPH, consistent with disrupted NADP(+) interactions; the N413K variant has the same activity pattern as Gln472 but with increased Vmax and kcat.\",\n      \"method\": \"Baculovirus expression of SNP variants, kinetic analysis (Km, Vmax, kcat), pH/temperature/cholate/Mg2+ stability assays, structural modeling\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzyme kinetics with multiple conditions and structural modeling, characterizing catalytic mechanism\",\n      \"pmids\": [\"19420133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Human FMO2 expressed in E. coli whole-cell biocatalysts catalyzes the selective N-oxidation of trifluoperazine to its N1-oxide and oxidizes propranolol; truncation of the C-terminal membrane-anchor region did not yield soluble FMO2 but affected recombinant protein levels.\",\n      \"method\": \"Heterologous expression in E. coli, substrate screening, biotransformation at 100 L scale with product isolation and purity analysis\",\n      \"journal\": \"Microbial cell factories\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with preparative-scale catalytic demonstration and product characterization\",\n      \"pmids\": [\"26062974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FMO2 directly interacts with SREBP1 at amino acids 217–296 of FMO2, competitively displacing SCAP from SREBP1, thereby blocking SREBP1 translocation from the ER to the Golgi and its subsequent proteolytic activation, thus suppressing de novo lipogenesis. This function is independent of FMO2 enzymatic activity. Hepatocyte-specific FMO2 knockout exacerbated steatosis, and FMO2 overexpression ameliorated NAFLD in mice.\",\n      \"method\": \"Co-IP, pulldown mapping (aa 217–296), hepatocyte-specific and global KO/overexpression mouse models, RNA-seq, SREBP1 translocation assay, competitive binding assay with SCAP\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct protein interaction mapping + competitive binding + KO/OE mouse phenotype with mechanistic readout, multiple orthogonal methods\",\n      \"pmids\": [\"37874228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FMO2 localizes to mitochondria-associated ER membranes (MAMs) in cardiomyocytes and forms a complex with IP3R2, Grp75, and VDAC1, maintaining ER–mitochondria contacts and regulating mitochondrial Ca2+ transfer for bioenergetics. FMO2 deletion worsened, and cardiac-specific FMO2 overexpression prevented, pathological cardiac hypertrophy in mice.\",\n      \"method\": \"MAM-targeted mass spectrometry, Co-IP (IP3R2-Grp75-VDAC1 complex), cardiac-specific KO and AAV9-overexpression mouse models, Ca2+ signaling assay, neonatal rat cardiomyocyte culture\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — MAM proteomics + Co-IP complex identification + KO/OE mouse phenotype with defined Ca2+ mechanism\",\n      \"pmids\": [\"40489543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FMO2 protects against doxorubicin-induced cardiomyopathy by stabilizing chromatin-associated XLF (XRCC4-like factor), thereby promoting DNA double-strand break repair. FMO2 KO exacerbated DOX-induced cardiac injury; cardiomyocyte-specific FMO2 overexpression mitigated it without compromising antitumor efficacy.\",\n      \"method\": \"FMO2 KO and cardiomyocyte-specific overexpression mouse models, transcriptome profiling, chromatin analysis, XLF stability assays, xenograft tumor model\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO/OE mouse models with defined molecular mechanism (XLF stabilization), single lab\",\n      \"pmids\": [\"40752568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FMO2 promotes angiogenesis in endothelial cells by regulating N-acetylornithine levels; N-acetylornithine inactivates NOTCH1 expression via transcriptional regulation of ATF3. EC-specific FMO2 compensation in FMO2-knockout mice restored angiogenesis in ischemic models and developing retina.\",\n      \"method\": \"Single-cell transcriptomics, EC-specific KO compensation, targeted metabolomics, NOTCH1/ATF3 transcriptional assay, ischemic model in vivo\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — metabolomics + genetic rescue + transcriptional mechanism, single lab\",\n      \"pmids\": [\"41053533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FMO2 promotes CCL19 expression in cancer-associated fibroblasts by competitively binding GYS1 (glycogen synthase 1), thereby preventing the PJA1 ubiquitin ligase from targeting GYS1 for proteasomal degradation; accumulated GYS1 activates NF-κB/p65-mediated CCL19 transcription, which drives tertiary lymphoid structure formation and CD8+ T cell/M1 macrophage infiltration.\",\n      \"method\": \"Co-IP (FMO2-GYS1-PJA1), ubiquitination assay, NF-κB/p65 reporter, mouse orthotopic HCC model, single-cell RNA-seq, spatial transcriptomics, CyTOF\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP interaction mapping + ubiquitination assay + in vivo rescue, single lab\",\n      \"pmids\": [\"40316306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CELF4 RNA-binding protein binds the 3′UTR of FMO2 mRNA, suppressing FMO2 expression; reduced FMO2 levels potentiate Smad2/3 phosphorylation downstream of TGF-β1 in cardiac fibroblasts, promoting fibrosis. CELF4 KO upregulated FMO2 and attenuated cardiac fibrosis.\",\n      \"method\": \"RNA pull-down, luciferase reporter assay (3′UTR), RIP assay, CELF4 KO mouse model, TGF-β1-stimulated cardiac fibroblasts, Western blot\",\n      \"journal\": \"BMC cardiovascular disorders\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — RNA pull-down + luciferase + in vivo KO with defined signaling readout, single lab\",\n      \"pmids\": [\"40610856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CELF1 RNA-binding protein binds FMO2 mRNA and its 3′UTR GU-rich element, promoting FMO2 mRNA decay; CELF1 silencing upregulated FMO2 and improved post-MI cardiac remodeling, while FMO2 overexpression reduced extracellular matrix deposition.\",\n      \"method\": \"RIP assay, RNA pull-down (biotinylated GU-rich element), actinomycin D mRNA stability assay, LAD-ligation MI mouse model, lentiviral FMO2 overexpression\",\n      \"journal\": \"Cardiovascular toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — RNA pull-down + mRNA stability + in vivo KO/OE with defined phenotype, single lab\",\n      \"pmids\": [\"40021568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Exercise training upregulates cardiac FMO2 through an AMPK→KLF4 transcriptional axis; KLF4 mediates FMO2 transcription; AAV9-mediated FMO2 knockdown abolished exercise-mediated cardiac protection against sympathetic overactivation-induced dysfunction and fibrosis.\",\n      \"method\": \"AAV9 FMO2 knockdown in vivo, AMPK activation experiments, KLF4 transcription factor identification, mouse model of sympathetic overactivation\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KD with defined upstream pathway and functional cardiac phenotype, single lab\",\n      \"pmids\": [\"39491669\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Human FMO2 is an NADPH-dependent flavoenzyme that, when full-length (FMO2*1 allele), catalyzes N- and S-oxygenation of xenobiotics in the lung; the predominant human allele encodes a catalytically inactive C-terminally truncated protein, but beyond its classical enzymatic role, full-length FMO2 also acts as a non-enzymatic scaffold that blocks SREBP1 ER-to-Golgi translocation to suppress hepatic lipogenesis, maintains ER–mitochondria (MAM) contacts via the IP3R2-Grp75-VDAC1 complex to regulate mitochondrial Ca2+ signaling, stabilizes chromatin-bound XLF to facilitate DNA repair in cardiomyocytes, and in cancer-associated fibroblasts sequesters GYS1 from PJA1-mediated ubiquitination to activate NF-κB/CCL19 signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FMO2 is a multifunctional ER-anchored flavoprotein that serves both as an NADPH-dependent monooxygenase catalyzing N- and S-oxygenation of xenobiotics and as a non-enzymatic scaffold regulating lipid metabolism, calcium signaling, DNA repair, and immune signaling. The full-length enzyme (encoded by the FMO2*1 allele) requires its C-terminal 64 residues for catalytic activity, as the predominant human allele (Q472X) produces a truncated, catalytically inactive protein that nonetheless localizes to ER membranes [PMID:9804831, PMID:11302936]. Independent of its enzymatic function, FMO2 competitively displaces SCAP from SREBP1 to block ER-to-Golgi translocation and suppress hepatic lipogenesis [PMID:37874228], maintains ER–mitochondria contacts via an IP3R2–Grp75–VDAC1 complex to regulate mitochondrial Ca²⁺ transfer in cardiomyocytes [PMID:40489543], stabilizes chromatin-bound XLF to promote DNA double-strand break repair [PMID:40752568], and sequesters GYS1 from PJA1-mediated ubiquitination to activate NF-κB/CCL19 signaling in cancer-associated fibroblasts [PMID:40316306]. FMO2 expression is transcriptionally induced by the AMPK–KLF4 axis and post-transcriptionally suppressed by the RNA-binding proteins CELF1 and CELF4, which promote FMO2 mRNA decay via 3′UTR binding [PMID:39491669, PMID:40021568, PMID:40610856].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing FMO2 as a catalytically distinct monooxygenase: recombinant rabbit FMO2 showed unique sulfoxidation kinetics and stereoselectivity compared with other FMO family members, defining it as a functionally autonomous enzyme rather than a redundant paralog.\",\n      \"evidence\": \"E. coli–expressed rabbit FMO2 with kinetic (Km, Vmax) and enantiomeric excess measurements of sulfoxidation products\",\n      \"pmids\": [\"8203899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human FMO2 substrate spectrum not yet characterized\", \"No structural basis for stereoselectivity\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Explaining why most humans lack pulmonary FMO2 activity: identification of the Q472X nonsense mutation in the major human allele showed the C-terminal region is indispensable for catalysis, a conclusion confirmed by expression of the equivalent truncation in macaque FMO2.\",\n      \"evidence\": \"cDNA cloning/sequencing, heterologous expression with catalytic assays, and primate comparative genomics [1998]; baculovirus-expressed macaque full-length vs. truncated FMO2 [2001]; genotype–protein–activity correlation in human lung microsomes [2000]\",\n      \"pmids\": [\"9804831\", \"11302936\", \"11042094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism by which C-terminal truncation abolishes catalysis unknown\", \"Frequency of functional FMO2*1 in non-African populations not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defining catalytic residues and cofactor interactions: characterization of S195L and N413K variants revealed that S195 is critical for NADPH binding affinity, refining the mechanistic model of FMO2 cofactor utilization.\",\n      \"evidence\": \"Baculovirus-expressed SNP variants with full kinetic profiling (Km for NADPH, Vmax, kcat) and thermal/pH/detergent stability assays\",\n      \"pmids\": [\"19420133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of FMO2 to confirm predicted cofactor contacts\", \"Impact of these variants in vivo unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealing an enzyme-independent scaffolding role in lipid metabolism: FMO2 directly binds SREBP1 (aa 217–296) and competitively displaces SCAP, blocking SREBP1 ER-to-Golgi translocation and suppressing de novo lipogenesis — a function independent of its monooxygenase activity.\",\n      \"evidence\": \"Co-IP with domain mapping, competitive binding assay, hepatocyte-specific KO/OE mouse models with NAFLD phenotyping, RNA-seq\",\n      \"pmids\": [\"37874228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the truncated Q472X protein retains SREBP1-binding capacity is untested\", \"Regulation of FMO2 expression in hepatocytes not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying the upstream transcriptional axis controlling cardiac FMO2: exercise-induced AMPK activation drives KLF4-mediated FMO2 transcription, and AAV9-mediated FMO2 knockdown abolished exercise-conferred cardiac protection.\",\n      \"evidence\": \"AAV9 FMO2 knockdown in vivo, AMPK activation experiments, KLF4 transcription factor identification, sympathetic overactivation mouse model\",\n      \"pmids\": [\"39491669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct KLF4 binding to FMO2 promoter not shown by ChIP\", \"Whether AMPK–KLF4 axis operates in non-cardiac tissues unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Establishing FMO2 as a MAM-resident scaffold for ER–mitochondria Ca²⁺ signaling: FMO2 localizes to MAMs and forms a complex with IP3R2–Grp75–VDAC1, maintaining mitochondrial Ca²⁺ transfer; cardiac-specific KO exacerbated and OE prevented pathological hypertrophy.\",\n      \"evidence\": \"MAM-targeted proteomics, Co-IP of complex components, cardiac-specific KO and AAV9-OE mouse models, Ca²⁺ imaging in neonatal rat cardiomyocytes\",\n      \"pmids\": [\"40489543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and direct vs. bridged interaction with each complex member unresolved\", \"Whether MAM function is enzymatic or purely scaffolding not dissected\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linking FMO2 to DNA repair: FMO2 stabilizes chromatin-bound XLF to facilitate NHEJ-mediated DNA double-strand break repair, protecting cardiomyocytes from doxorubicin-induced damage.\",\n      \"evidence\": \"FMO2 KO and cardiomyocyte-specific OE mouse models, chromatin analysis, XLF stability assays, xenograft tumor model\",\n      \"pmids\": [\"40752568\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of XLF stabilization (direct binding vs. indirect) not defined\", \"Single-lab finding awaiting independent replication\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealing a non-enzymatic role in immune microenvironment remodeling: in cancer-associated fibroblasts, FMO2 sequesters GYS1 from PJA1-mediated ubiquitination, enabling GYS1 accumulation that activates NF-κB/p65-driven CCL19 transcription and tertiary lymphoid structure formation.\",\n      \"evidence\": \"Co-IP (FMO2–GYS1–PJA1), ubiquitination assay, NF-κB reporter, orthotopic HCC mouse model, scRNA-seq, spatial transcriptomics, CyTOF\",\n      \"pmids\": [\"40316306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FMO2–GYS1 binding interface not mapped\", \"Relevance outside hepatocellular carcinoma unclear\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defining post-transcriptional regulation of FMO2: CELF1 and CELF4 independently bind FMO2 mRNA (3′UTR GU-rich elements) and promote its decay, establishing mRNA stability as a key regulatory node for FMO2 levels in cardiac fibroblasts.\",\n      \"evidence\": \"RIP, RNA pull-down with biotinylated elements, luciferase 3′UTR reporter, actinomycin D decay assay, CELF KO/KD mouse models with cardiac phenotyping\",\n      \"pmids\": [\"40021568\", \"40610856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CELF1 and CELF4 target overlapping or distinct sites on FMO2 3′UTR not compared\", \"Impact of post-transcriptional regulation on non-cardiac FMO2 functions untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how FMO2's multiple non-enzymatic scaffold functions (SREBP1 binding, MAM tethering, XLF stabilization, GYS1 sequestration) are coordinated or mutually exclusive across cell types, and whether the prevalent Q472X truncated human protein retains any of these scaffold activities.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of human FMO2 to map overlapping vs. separate interaction surfaces\", \"Truncated Q472X protein has never been tested for non-enzymatic functions\", \"No systems-level study integrating enzymatic and scaffolding roles across tissues\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [1, 2, 5, 6]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 8, 11]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [7, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 7, 8]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:1430728\", \"supporting_discovery_ids\": [1, 5, 6, 7]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 8, 11, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 9]}\n    ],\n    \"complexes\": [\n      \"IP3R2-Grp75-VDAC1 MAM complex\"\n    ],\n    \"partners\": [\n      \"SREBP1\",\n      \"SCAP\",\n      \"IP3R2\",\n      \"GRP75\",\n      \"VDAC1\",\n      \"XLF\",\n      \"GYS1\",\n      \"PJA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}